Adverse Childhood Experiences and Adult Health Outcomes Among Veteran and Non-Veteran Women.

Related Articles

Adverse Childhood Experiences and Adult Health Outcomes Among Veteran and Non-Veteran Women.

J Womens Health (Larchmt). 2015 Sep;24(9):723-9

Authors: McCauley HL, Blosnich JR, Dichter ME

Abstract
BACKGROUND: Women veterans represent a vulnerable population with unique health needs and disparities in access to care. One constellation of exposures related to subsequent poor health includes adverse childhood experiences (ACEs; e.g., physical and sexual child abuse), though research on impacts of ACEs among women veterans is limited.
METHODS: Data were drawn from the 2010 Behavioral Risk Factor Surveillance System for the 11 states that included the ACE module (n=36,485). Weighted chi-squared tests and multivariable logistic regression were used to assess the prevalence of ACEs among women veterans compared with women non-veterans and differences in the following outcomes, controlling for ACEs: social support, inadequate sleep, life satisfaction, mental distress, smoking, heavy alcohol use, obesity, diabetes, cardiovascular disease symptoms, asthma, and disability.
RESULTS: Women veterans (1.6% of the total sample) reported a higher prevalence of 7 out of 11 childhood adversities and higher mean ACE score than women non-veterans. Women veterans were more likely to be current smokers and report a disability, associations which were attenuated when controlling for ACE.
CONCLUSIONS: Despite women veterans’ higher prevalence of ACE, their health outcomes did not differ substantially from non-veterans. Further research is needed to understand the intersections of traumatic experiences and sources of resilience over the lifecourse among women veterans.

PMID: 26390379 [PubMed – in process]

View full post on pubmed: asthma

Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada – Lung Disease News


Lung Disease News

Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada
Lung Disease News
GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma, have just been granted Canadian approval for Breo Ellipta, a once-a-day maintenance treatment for asthma in patients who are at least 18 years old and have reversible …

and more »

View full post on asthma – Google News

Adult Orbital Xanthogranulomatous Disease: A Review with Emphasis on Etiology, Systemic Associations, Diagnostic Tools, and Treatment.

Adult Orbital Xanthogranulomatous Disease: A Review with Emphasis on Etiology, Systemic Associations, Diagnostic Tools, and Treatment.

Dermatol Clin. 2015 Jul;33(3):457-63

Authors: Kerstetter J, Wang J

Abstract
Adult orbital xanthogranulomatous diseases are rare entities and encompass a group of disorders with varying manifestations that are poorly understood. Taken as a group, there are non-Langerhans histiocytic disorders (type II) that are diagnosed histologically by the presence of foamy histiocytes, Touton giant cells, and varying degrees of fibrosis. Based on the accompanying systemic associations, there are 4 main categories of adult xanthogranulomatous disease: adult-onset xanthogranuloma, adult-onset asthma and periocular xanthogranuloma, necrobiotic xanthogranuloma, and Erdheim-Chester disease. Herein, we discuss the etiopathogenesis, systemic associations, methods of diagnosis, and treatment options for these disorders.

PMID: 26143425 [PubMed – in process]

View full post on pubmed: asthma

FDA Committee Recommends Approval Of Nucala For Adult Asthma Patients – Lung Disease News


Lung Disease News

FDA Committee Recommends Approval Of Nucala For Adult Asthma Patients
Lung Disease News
An FDA advisory committee recently voted unanimously to approve Nucala for the treatment of severe asthma with eosinophilic inflammation in patients 18 and older. The committee, however, decided against the use of the therapy in adolescents aged …
GSK's new asthma biologic gains FDA panel backingPMLiVE

all 2 news articles »

View full post on asthma – Google News

FDA Rejects GSK’s Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use … – Lung Disease News


Lung Disease News

FDA Rejects GSK's Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use
Lung Disease News
GSK Incruse Ellipta COPD The U.S. Food and Drug Administration (FDA) ruled against the use of GlaxoSmithKline's new drug combination Breo Ellipta in asthma patients between the ages of 12 and 17. However, the Pulmonary-Allergy Drugs Advisory …

View full post on asthma – Google News

Work-related asthma goes unaddressed in many adult patients – Clinical Advisor


HCPLive

Work-related asthma goes unaddressed in many adult patients
Clinical Advisor
HealthDay News — In adult patients diagnosed with asthma, only 15% discuss with their provider how their jobs may affect their disease, despite that nearly half have asthma that is possibly work-related, results of a study published in the Annals of
Work-related Asthma UnderdiagnosedHCPLive
Many workers fear losing their jobs if they talk about their work-related asthmaExaminer.com

all 3 news articles »

View full post on asthma – Google News